Provided by Tiger Trade Technology Pte. Ltd.

ADC Therapeutics SA

3.70
-0.2600-6.57%
Post-market: 3.700.00000.00%19:42 EDT
Volume:1.01M
Turnover:3.74M
Market Cap:470.06M
PE:-3.30
High:4.00
Open:3.89
Low:3.61
Close:3.96
52wk High:4.98
52wk Low:1.05
Shares:127.04M
Float Shares:92.24M
Volume Ratio:1.12
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1200
EPS(LYR):-1.1224
ROE:-705.53%
ROA:-20.56%
PB:-2.53
PE(LYR):-3.30

Loading ...

ADC Therapeutics Sa - in Event of Change of Control, Healthcare Royalty Will Continue to Receive Royalties by Acquirer Until Original Cap Is Reached

THOMSON REUTERS
·
Feb 23

ADC Therapeutics Sa - Anticipate Meaningful Growth Beginning 2027, Potential Peak Revenue in US Could Reach $600 Mln to $1 Bln Annually

THOMSON REUTERS
·
Feb 23

ADC Therapeutics Sa - Healthcare Royalty Granted Warrants to Purchase About 9.8 Mln Common Shares, With Exercise Price of $3.81 per Share

THOMSON REUTERS
·
Feb 23

ADC Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Feb 03

RBC Capital Sticks to Their Buy Rating for ADC Therapeutics (ADCT)

TIPRANKS
·
Jan 23

ADC Therapeutics Projects Cash Runway Through 2028 with 2025 Revenue at $73 Million

Reuters
·
Jan 09

ADC Therapeutics Grants Stock Options to New Employee

Reuters
·
Jan 03

ADC Therapeutics Sa - Selling Shareholders May Offer 14,696,253 Common Shares From Time to Time- SEC Filing

THOMSON REUTERS
·
Dec 13, 2025

ADC Therapeutics Reports 89.8% Response Rate in ZYNLONTA and Glofitamab Phase 1b Trial for r/r DLBCL

Reuters
·
Dec 06, 2025

Why Is ADC Therapeutics Plunging Today

Benzinga_recent_news
·
Dec 04, 2025

Crude Oil Gains 1%; Macy's Reports Strong Q3 Results

Benzinga
·
Dec 04, 2025

ADC Therapeutics Down Nearly 30%, on Pace for Largest Percent Decrease in Almost a Year -- Data Talk

Dow Jones
·
Dec 04, 2025

ADC Therapeutics Shares Fall After Two Deaths in Trial for Blood Cancer Treatment

Dow Jones
·
Dec 03, 2025

ADC Therapeutics Says Updated Data for Drug Supports Potential Best-in-Class Regimen in Lymphoma Patients

MT Newswires Live
·
Dec 03, 2025

ADC Therapeutics Sa - Lotis-7 Trial on Track for Complete Enrollment in 1H 2026

THOMSON REUTERS
·
Dec 03, 2025

ADC Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial of Zynlonta® in Combination With Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
Dec 03, 2025

ADC Therapeutics Announces LOTIS-7 Trial Update on ZYNLONTA Combination in Relapsed DLBCL

Reuters
·
Dec 03, 2025

ADC Therapeutics to Provide Update on Lotis-7 Clinical Trial

THOMSON REUTERS
·
Dec 03, 2025

ADC Therapeutics files to sell 14.7M common shares for holders

TIPRANKS
·
Nov 11, 2025

BRIEF-ADC Therapeutics SA - Selling Shareholders May Offer 14.7 Million Common Shares - SEC Filing

Reuters
·
Nov 11, 2025